Danaher expects about $350M in tariff costs; Alumis, Acelyrin adjust deal terms
Plus, news about Invivyd:
Danaher’s tariffs hit: The life sciences company currently expects the costs of tariffs to be “something like $350 million” in 2025 …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
